Actively Recruiting
Topical Multivitamin Serum for Skin Heath
Led by Erevna Innovations Inc. · Updated on 2026-02-05
30
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Skin boosters are injectable and topical treatments designed to improve dermal quality and restore skin health. These products typically include hyaluronic acid formulations, biostimulatory agents, platelet-rich plasma (PRP), growth factors, and polynucleotides. Their growing use in aesthetic medicine is supported by their diverse mechanisms of action and routes of administration. One such category of interest includes polynucleotide-based therapies, most notably Polydeoxyribonucleotide (PDRN). Derived from the DNA of salmon or trout, PDRN exhibits dual regenerative and anti-inflammatory properties. Mechanistically, it promotes tissue repair by supplying nucleotides essential for DNA synthesis and activates adenosine A2A receptors, thereby enhancing angiogenesis and mitigating inflammation. Clinically, PDRN has been applied in aesthetic medicine for skin rejuvenation, where it improves elasticity, texture, and reduces fine lines, as well as in wound healing and scar remodeling, supporting its integration into advanced bioregenerative protocols. Among such agents, VAMP™ ADVANCED Topical Multivitamin Serum is formulated to improve hydration, elasticity, and overall skin radiance through a proprietary blend of amino acids, vitamins, and peptides. While preliminary data suggest potential benefits, robust peer-reviewed clinical studies remain limited. This study seeks to evaluate the efficacy of topical application of VAMP™ ADVANCED Topical Multivitamin Serum following microneedling in skin rejuvenation.
CONDITIONS
Official Title
Topical Multivitamin Serum for Skin Heath
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand and willingly consent to participate in the study
- Interested in improving skin quality
- Immune-competent adult aged 22 years or older
- Intend to undergo treatment to improve facial skin appearance
- Willing to follow pre-visit instructions including shaving facial area if male
- Female participants of childbearing potential agree to use effective birth control during the study and take urine pregnancy tests at baseline and before treatments
- Negative urine pregnancy test at baseline for women of childbearing potential
- Stable lifestyle and skincare routine for at least 4 weeks prior to the study
You will not qualify if you...
- Allergy or sensitivity to VAMP ADVANCED serum components, including sodium hyaluronate, peptides, polynucleotides, or excipients
- Allergy or intolerance to topical anesthetics or lidocaine
- History of severe allergic reactions like anaphylaxis or angioedema
- History of hypertrophic scars, keloids, or post-inflammatory hyperpigmentation after cosmetic treatments
- Tattoos, piercings, or skin bleaching in the treatment area that interfere with assessments
- Known pigmentary instability or adverse reactions to microneedling
- Cosmetic or dermatologic treatments in the treatment area within specified time frames (e.g., dermal fillers within 12 months, lasers or peels within 6 months)
- Use of topical corticosteroids, retinoids, or depigmenting agents in the treatment area within 4 weeks
- Immunosuppressive therapy, systemic corticosteroids, or chemotherapy within 3 months
- History of autoimmune, collagen vascular, or bleeding disorders
- Current pregnancy, breastfeeding, or intent to become pregnant during the study
- Participation in another clinical trial within 30 days
- Psychological or cognitive conditions interfering with consent or protocol compliance
- Recent weight loss program or GLP-1 agonist therapy initiation
- Active skin conditions worsened by microneedling
- Study personnel or family members involved in the study
- Allergy to fish or seafood due to presence of marine-derived PDRN
- History of cancer or radiation near treatment area
- Heavy smoking (more than 12 cigarettes per day)
- Presence of diseases or lesions near the treatment area that affect safety or efficacy
- Use of medications that prolong bleeding within 14 days before injection, except certain allowed medications
- Recent chemotherapy, immunosuppressive agents, or systemic corticosteroids
- Hormonal therapy changes or instability within 3 months prior to screening
- Use of topical or systemic retinoids near baseline visit
- Pregnancy or breastfeeding during study duration
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Erevna Innovations Inc.
Montreal, Quebec, Canada, H3Z 1C3
Actively Recruiting
Research Team
L
Laura Raco
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here